Welcome to our dedicated page for TG Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, NY. The company's Chairman and CEO, Michael S. Weiss, will engage in a fireside chat on Monday, September 8, 2025, at 10:30am ET.
Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ: TGTX) has completed its previously announced $100 million share repurchase program, having bought back approximately 3.5 million shares at an average price of $28.55 per share. The program, which was initiated in August 2024, has now been fully executed, with approximately $78 million of stock repurchased in August alone.
The company's Board of Directors has authorized a new $100 million share repurchase program, which will be executed through open market purchases and private transactions. Management believes current market prices undervalue BRIUMVI's multibillion-dollar potential and the company's long-term growth prospects.
TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming Cantor Global Healthcare Conference in New York, NY from September 3-5, 2025. Michael S. Weiss, the company's Chairman and CEO, will engage in a fireside chat on Wednesday, September 3, 2025, at 10:20am ET.
Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website.
TG Therapeutics (NASDAQ: TGTX) reported strong Q2 2025 financial results, with total revenue reaching $141.1 million, primarily driven by BRIUMVI U.S. net revenue of $138.8 million - representing 91% growth year-over-year and 16% growth over Q1 2025.
The company raised its full-year 2025 guidance, now targeting BRIUMVI U.S. net revenue of $570-575 million and total global revenue of approximately $585 million. TG Therapeutics achieved net income of $28.2 million for Q2 2025 and reported a strong cash position of $278.9 million.
Key developments include BRIUMVI's expansion outside the U.S., with approvals in the EU, UK, Switzerland, and Australia. The company is advancing its pipeline with new clinical trials, including a Phase 3 program for consolidated BRIUMVI dosing and development of a subcutaneous formulation.
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, August 4, 2025, at 8:30 AM ET to discuss their second quarter 2025 financial results and provide a business outlook. The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer.
Investors can join via phone at 1-877-407-8029 (U.S.) or 1-201-689-8029 (international). A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days afterward. Financial results will be released prior to the call.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies:
1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree
2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox
3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley
All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.